Skip to main content

Advertisement

Table 2 Hematologic toxicities (nadir) and elevation of liver enzymes (peak) during treatment

From: Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes

  N/A Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
During chemotherapy (n = 18)       
  Elevation ALT 4 (22%) 9 (50%) 5 (28%) 0 0 0
  Elevation AST 5 (28%) 10 (56%) 3 (17%) 0 0 0
  Anemia (Hgb) 2 (11%) 3 (17%) 9 (50%) 4 (22%) 0 0
  Thrombocytopenia 2 (11%) 13 (72%) 2 (11%) 1 (6%) 0 0
  Neutropenia 2 (11%) 12 (67%) 0 2 (11%) 2 (11%)* 0
During RT (n = 20)       
  Elevation ALT 5 (25%) 11 4 (20%) 2 (10%) 0 0
  Elevation AST 5 (25%) 11 4 (20%) 0 0 0
  Anemia (Hgb) 0 3 (15%) 10 (50%) 6 (30%) 1 (5%) 0
  Thrombocytopenia 0 5 (25%) 10 (50%) 4 (20%) 1(5%) 0
  Neutropenia 2 (10%) 6 (30%) 6 (30%) 4 (20%) 2 (10%) 0
  Hypokalemia 6 (30%) 6 (30%) 1 (5%) 3 (15%) 4 (20%) 0
6 weeks after RT (n = 20)       
  Elevation ALT 9 (45%) 5 (25%) 5 (25%) 0 1 (5%) 0
  Elevation AST 9 (45%) 5 (25%) 5 (25%) 0 1 (5%) 0
  Anemia (Hgb) 6 (30%) 3 (15%) 8 (40%) 3 (15%) 0 0
  Thrombocytopenia 6 (30%) 7 (35%) 5 (25%) 1 (5%) 1 (5%) 0
  Neutropenia 7 (35%) 9 (45%) 1 (5%) 2 (10%) 1 (5%) 0
  1. Common terminology criteria for adverse events (CTCAE) version 4.03 (2010).
  2. * febrile neutropenia.
  3. Abbreviations: N/A Information not available at time of analysis, RT Radiotherapy; Hgb Hemoglobin, ALT Alanine aminotransferase, AST Aspartate aminotransferase.